Efficacy and toxicity of Iodine-125 seed implantation for lymph node recurrence secondary to esophageal cancer after radiotherapy: a multicenter retrospective study

Table 4 Multivariate analysis of prognostic factors

Endpoints	Factor	HR (95% CI)	P value
LPFS	KPS (≥ 90 vs. ≤ 80)	0.662 (0.446–0.983)	0.041
	Short-term efficacy (SD + PD vs. CR + PR)	1.513 (1.002–2.284)	0.049
OS	Initial tumor stage (I + II vs. III + IVA)	0.617 (0.395–0.964)	0.034
	Lesion volume (≥ 22.2 vs. < 22.2 cm³)	1.679 (1.099–2.566)	0.017
	Short-term efficacy (SD + PD vs. CR + PR)	1.876 (1.222–2.878)	0.004

P values were calculated using an adjusted Cox proportional hazard model with the following factors: age (≥ 63 vs. < 63 y), KPS (≥ 90 vs. ≤ 80), initial tumor stage (III + IVA vs. I + II), number of lymph nodes (single vs. multiple), lesion volume (≥ 22.2 vs. < 22.2 cm³), prescribed dose (> 120 vs. ≤ 120 Gy), D90 dose (> 130.3 vs. ≤ 130.3 Gy), the time interval between radioactive Iodine-125 seed implantation and previous radiotherapy (> 13 vs. ≤ 13 months), seed activity (> 0.6 vs. ≤ 0.6 mCi), the boundary of recurrent lymph nodes (non-clear vs. clear) and short-term efficacy (SD + PD vs. CR + PR)
KPS karnofsky performance status, CR complete response, PR partial response, SD stable disease, PD progressive disease, LPFS local progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval

ISSN: 1748-717X